Current Headlines

  1. Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms And Retains Talent And Infrastructure From Repare Therapeutics To Accelerate Development Of Multi-Modal Antibody Drug Conjugates 5/1/2025

    DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) to (i) in-license Repare’s discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the “Transaction”).

  2. Everest Medicines Announces New Drug Application Approval Of VELSIPITY For Adults With Moderately To Severely Active Ulcerative Colitis In Hong Kong 5/1/2025

    Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, China, has officially approved the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

  3. Folia Health And Inspire Are Partnering To Bring Personalized Home Health Observations To The Forefront Of Patient Focused Drug Development Research 4/30/2025

    Folia Health, the pioneer of patient-driven Home Reported Outcomes (HRO), has partnered with Inspire, the world's leading online health community and real-world data platform, to uniquely empower patients and caregivers with the opportunity to contribute a highly personalized form of structured at-home health observations data to accelerate patient-focused drug development research.

  4. Sapient Launches DynamiQ As Its Next-Generation Data Insights Engine For Drug Discovery And Development 4/30/2025

    Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ Insights Engine, which increases the speed, versatility, and depth of analyses that Sapient can perform to inform drug discovery and precision drug development strategies.

  5. [C.S Group] : Launches Antcin A-Based Veterinary Drug Initiative Across Taiwan And China 4/30/2025

    Cordyceps Sunshine Biotech Holdings Co., Ltd.【C.S Group】 announced a major milestone in veterinary drug development at the "Pharmacological Progress Conference for Taiwanofungus camphoratus Applications in the Pet Market," co-hosted with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA).

  6. Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development 4/29/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production.

  7. Pointing The Way Towards The Future Of Drug Development 4/28/2025

    Can AI and automation shorten the time it takes to develop new drugs? Ola Spjuth combines his academic expertise in data-driven drug development with entrepreneurship to help the pharmaceutical industry capitalise on the potential of new technologies.

  8. Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer's Drug 4/28/2025

    Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.

  9. Intellomx Launches Swarm-Based AI Platform To Accelerate And De-Risk Novel Target And Drug Discovery 4/28/2025

    Intellomx (Intelligent OMICS Ltd) today announced the deployment of Intellomx Pilot, delivering rapid identification of novel drugs arising from its existing precision therapeutic target identification capability, offering pharmaceutical innovators a powerful tool to streamline and de-risk the drug discovery process.

  10. Tempus Introduces Loop, An AI-Powered Target Discovery And Validation Platform 4/28/2025

    Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation.